FDA Resumes Deramiocel Review, Sets August 2026 PDUFA Date for Capricor's DMD Therapy
Event summary
- FDA lifted the Complete Response Letter for Deramiocel and set a new PDUFA target action date of August 22, 2026.
- Deramiocel's BLA is supported by positive HOPE-3 Phase 3 trial results, including achievement of primary and secondary endpoints.
- Capricor expects to be eligible for a Priority Review Voucher upon potential approval of Deramiocel.
- Deramiocel is an investigational cell therapy targeting both skeletal and cardiac manifestations of Duchenne muscular dystrophy.
The big picture
Capricor's progress with Deramiocel reflects the growing focus on cell-based therapies for rare diseases, particularly those with limited treatment options. The FDA's resumption of review and the potential for a Priority Review Voucher highlight the strategic importance of Deramiocel in addressing both skeletal and cardiac manifestations of Duchenne muscular dystrophy. The outcome of this regulatory process could set a precedent for other cell therapy candidates in development.
What we're watching
- Regulatory Approval
- Whether the FDA will approve Deramiocel by the August 22, 2026 PDUFA date, given the positive HOPE-3 trial results.
- Commercialization Strategy
- How Capricor will leverage the potential Priority Review Voucher to accelerate market entry and commercialization of Deramiocel.
- Competitive Landscape
- The pace at which Capricor can establish Deramiocel as a first-in-class therapy in the Duchenne muscular dystrophy market.
Related topics